Home
Subscription
October 2024 issue
September 2024 issue
August 2024 issue
July 2024 issue
June 2024 issue
May 2024 issue
April 2024 issue
April 1, 2024 issue
March 2024 issue
February 2024 issue
January 2024 issue
BACK ISSUES
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
|
2022 Issues
December 2022 Issue
• Feature: Christmas, Blessings, and Giving
• "O Holy Night"
• Appreciation
• Index for Volume 17, 2022
November 2022 Issue
• Feature: Paying $10 Billion Means Never Having to Say You are Sorry! No Accountability!
• Continued Deception and Arrogance of CVS
• Smoking – The Neglected Pandemic
• A Bipartisan Political Message
October 2022 Issue
• Feature: Rescuing Independent Pharmacy: Part 4 - The Inspiration of Independents
• Politics, Platforms, and Polls
September 2022 Issue
• Feature: Rescuing Independent Pharmacy: Part 3
August 2022 Issue
• Feature: Concepts and Strategies for Rescuing and Rebuilding Independent Pharmacy
July 2022 Issue
• Feature: Independence Day and Independents Day – THE FUTURE OF PHARMACY: THE SUICIDE OF OUR ONCE-NOBLE PROFESSION – UNLESS THERE IS A REVOLUTION!
June 2022 Issue
• Feature: The End of a Distinguished Era for the Philadelphia College of Pharmacy – And Best Wishes for Success in the Next Era!
• New Therapeutic Agents Marketed in the United States in 2021
May 2022 Issue
• Feature: Which is Stronger (Weaker) – AMA or APhA? It Doesn't Matter – They Need a Synergistic Working Relationship!
• Walgreens Passes CVS in a Metric on the Race to the Bottom!
• Paxlovid – A Blemished Success Story
April 2022 Issue
• Feature: LIVE and IN-PERSON
• Chain Lowlights
• Does Anyone Monitor the Regulators?
March 2022 Issue
• Feature: COVID-19 Vaccine Follies – Are There Really Any "Experts"?
• "CVS Ousts Executives After Probe"
• New Drug Review: Atogepant (Qulipta)
February 2022 Issue
• Feature: Medication Errors – If the Public Knew…
• Oral Antivirals for COVID-19 – We Must Learn from Experience
• New Drug Review: Nirmatrelvir/ritonavir (Paxlovid)
January 2022 Issue
• Feature: COVID-19 – Two Years Later
• Continued PBM Deception and Fraud
• New Drug Review: Aducanumab-avwa (Aduhelm)
| |
